These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 30170567)

  • 41. Placental Growth Factor and Soluble, Fms-Like Tyrosine Kinase-1 in Preeclampsia: A Case-Cohort (PEARL) Study.
    Fillion A; Guerby P; Lachance C; Comeau MP; Bussières MC; Doucet-Gingras FA; Zérounian S; Demers S; Laforest G; Menzies D; Bujold E
    J Obstet Gynaecol Can; 2020 Oct; 42(10):1235-1242. PubMed ID: 32718871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
    Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
    Wikström AK; Larsson A; Eriksson UJ; Nash P; Nordén-Lindeberg S; Olovsson M
    Obstet Gynecol; 2007 Jun; 109(6):1368-74. PubMed ID: 17540809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth.
    Smith GC; Crossley JA; Aitken DA; Jenkins N; Lyall F; Cameron AD; Connor JM; Dobbie R
    Obstet Gynecol; 2007 Jun; 109(6):1316-24. PubMed ID: 17540803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does a sFlt-1/PlGF ratio result > 655 before 34 weeks' gestation necessitate preterm delivery within 2 days? A retrospective observational study.
    Siepen C; Brennecke S
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2371047. PubMed ID: 38926094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
    Lai J; Garcia-Tizon Larroca S; Peeva G; Poon LC; Wright D; Nicolaides KH
    Fetal Diagn Ther; 2014; 35(4):240-8. PubMed ID: 24853452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
    Stepan H; Hund M; Andraczek T
    Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam.
    Nguyen TH; Bui TC; Vo TM; Tran QM; Luu LT; Nguyen TD
    Pregnancy Hypertens; 2018 Oct; 14():37-42. PubMed ID: 30527116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study.
    Bækgaard Thorsen LH; Bjørkholt Andersen L; Birukov A; Lykkedegn S; Dechend R; Stener Jørgensen J; Thybo Christesen H
    J Matern Fetal Neonatal Med; 2020 Apr; 33(8):1377-1384. PubMed ID: 30173595
    [No Abstract]   [Full Text] [Related]  

  • 52. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia.
    Verlohren S; Herraiz I; Lapaire O; Schlembach D; Zeisler H; Calda P; Sabria J; Markfeld-Erol F; Galindo A; Schoofs K; Denk B; Stepan H
    Hypertension; 2014 Feb; 63(2):346-52. PubMed ID: 24166751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.
    Heazell AE; Hayes DJ; Whitworth M; Takwoingi Y; Bayliss SE; Davenport C
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012245. PubMed ID: 31087568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First trimester TTR-RBP4-ROH complex and angiogenic factors in the prediction of small for gestational age infant's outcome.
    Fruscalzo A; Frommer J; Londero AP; Henze A; Schweigert FJ; Nofer JR; Steinhard J; Klockenbusch W; Schmitz R; Raila J
    Arch Gynecol Obstet; 2017 May; 295(5):1157-1165. PubMed ID: 28337595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of fetal growth restriction using estimated fetal weight vs a combined screening model in the third trimester.
    Miranda J; Rodriguez-Lopez M; Triunfo S; Sairanen M; Kouru H; Parra-Saavedra M; Crovetto F; Figueras F; Crispi F; Gratacós E
    Ultrasound Obstet Gynecol; 2017 Nov; 50(5):603-611. PubMed ID: 28004439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
    Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
    PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Independent risk factors for a small placenta and a small-for-gestational-age infant at 35-41 weeks of gestation: An association with circulating angiogenesis-related factor levels at 19-31 weeks of gestation.
    Hirashima C; Ohkuchi A; Takahashi K; Suzuki H; Shirasuna K; Matsubara S
    J Obstet Gynaecol Res; 2017 Aug; 43(8):1285-1292. PubMed ID: 28613009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.